BUZZ-IntelliPharmaCeutics International Inc: FDA imposes new conditions

Fri Jun 19, 2015 10:29am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Generic drug maker's shares down 7 pct at $3.19

** FDA indicated that IntelliPharmaCeutics' generic Attention Deficit Hyperactivity Disorder treatment will have to meet new conditions to prove it is as effective as existing therapy, company says

** Says FDA decision affects 4 out of 6 doses, which have only conditional approval

** Says will pursue "all reasonable courses of action" to get final approval, along with its U.S. marketing partner Par Pharmaceutical Inc

** Up to Thursday's close, stock had risen nealry 53 pct this year